The article provides an analysis of the latest antiepileptic drug eslicarbazepine acetate (ESL) for the treatment of focal epilepsy in adults as monotherapy and adjunctive therapy. Pharmacokinetics, pharmacodynamics, drug-drug interactions, indications and dosage regimen are described. The authors present the latest data on the efficacy, tolerability and safety of ESL including an exploratory pooled analysis of data from 14 European clinical practice studies (Euro-Esli) as well as their own observations of 34 patients receiving ESL in monotherapy or combination therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro201811841140-145 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eslicarbazepine acetate, an alternative for patients with trigeminal neuralgia with hyponatremia induced by carbamazepine or oxcarbazepine.
J Family Med Prim Care
November 2024
Centro de Salud Trujillo, Trujillo (Cáceres), Spain.
Serious adverse effects of selected antiseizure medications used for treatment of focal onset seizures.
Expert Opin Drug Saf
December 2024
Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Introduction: The third-generation antiseizure medications used for the treatment of focal seizures, lacosamide, eslicarbazepine acetate, perampanel, brivaracetam, and cenobamate, may elicit serious adverse reactions which could be preventable if a prescriber is acquainted with the risk factors.
Areas Covered: The literature search was conducted in MEDLINE, SCOPUS, and EBSCO databases, without time and language restrictions. Only clinical studies, observational human studies, case reports, and case series that reported serious adverse drug reactions and risk factors were considered.
A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1).
Front Pharmacol
September 2024
Department of Pharmacy, The 305 Hospital of PLA, Beijing, China.
Article Synopsis
- The study investigates adverse events (AEs) associated with eslicarbazepine acetate (ESL), a medication approved in 2013 for partial-onset seizures, using data from the FDA Adverse Event Reporting System (FAERS).
- It employs various statistical methods to identify significant AE signals and examines demographic factors like gender and age related to these events.
- The analysis revealed 5,719 AE reports, with notable issues related to nervous system disorders occurring mostly within the first month of treatment, resulting in 86 significant positive signals.
Assessing the Effectiveness of Eslicarbazepine Acetate in Reducing Audiogenic Reflex Seizures in the GASH/Sal Model of Epilepsy.
Biomedicines
May 2024
Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug indicated as monotherapy for adults with newly diagnosed epilepsy and as adjunctive therapy for the treatment of partial seizures. Our aim was to assess the effectiveness and safety of both acute and repeated ESL administration against reflex audiogenic seizures, as shown by the Genetic Audiogenic Seizures Hamster from Salamanca (GASH/Sal). Animals were subject to the intraperitoneal administration of ESL, applying doses of 100, 150 and 200 mg/kg for the acute study, whereas a daily dose of 100 mg/kg was selected for the subchronic study, which lasted 14 days.
View Article and Find Full Text PDFLong-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.
Clin Transl Sci
May 2024
BIAL - Portela & Cª, S.A, Coronado, Portugal.
A post hoc analysis of data from Asian patients included in the study BIA-2093-304 was conducted to evaluate the long-term safety/tolerability and efficacy of adjunctive eslicarbazepine acetate (ESL) in adult Asian patients with refractory focal seizures. Part I was a randomized controlled trial, in which patients received ESL (800 or 1200 mg once daily [QD]) or placebo, assessed over a 12-week maintenance period. Patients completing Part I could enter two open-label extension periods (Part II, 1 year; Part III, ≥2 years), during which all received ESL (400-1600 mg QD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!